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Objectives. To investigate the efficacy of infliximab in the treatment of severe calcium pyrophosphate deposition diseases (CPPD).
Methods. Two patients with severe CPPD and diffuse idiopathic skeletal hyperostosis- (DISH-) like phenotype are described.
Both patients were resistant to therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). Both patients were treated with
infliximab, a TNF-𝛼 receptor antagonist, for nine years. Results. Treatment with infliximab resulted in major clinical and laboratory
improvements without relevant side effects. Conclusions. These results suggest that infliximab may be an effective treatment of
severe CPDD.
1. Introduction
Calcium pyrophosphate dehydrate deposition disease
(CPPD) is caused by calcium pyrophosphate dehydrate (CPP
crystals) crystal deposition. Three main forms of CPPD are
usually described: acute pseudogout, inflammatory chronic
arthropathy, and osteoarthritis-like disease [1]. An additional
CPPD phenotype characterized by peripheral and axial
enthesopathic calcifications was described by Resnick and
others [2–5]. Pseudogout, characterized by acute attacks of
inflammatory arthritis, mainly in wrists and knees, is some-
times severe and can be refractory to current nonbiological
treatments. Treatment of CPPD depends on the clinical
manifestations and disease severity, and several drugs
may be used, like nonsteroidal anti-inflammatory drugs
(NSAIDs), intra-articular or systemic steroids, methotrexate,
hydroxychloroquine, and colchicine [6]. However, severe
cases of CPPD refractory to classic treatments have been
reported and, more recently, other therapeutic approaches
have been described that may be effective in these conditions.
The administration of the recombinant IL-1R antagonist
anakinra and other IL-1 targeting drugs has been shown
to be effective in microcrystalline diseases [7]. The admin-
istration of anakinra (interleukin-1 receptor antagonist) or
canakinumab (anti-interleukin-1 beta) to patients with acute
gout led to rapid resolution of inflammation [8, 9] and
anakinra treatment was efficacious in the treatment of two
patients with severe episodes of pseudogout, preventing the
occurrence of new flares of the disease if administered
continuously in a patient with end-stage renal failure [10, 11].
Infliximab is a TNF-𝛼 receptor antagonist used success-
fully to treat severe forms of inflammatory arthritis, namely,
ankylosing spondylitis [12] and rheumatoid arthritis [13].
Assuming that there is a role for TNF-𝛼 in crystal induced
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arthritis, we have treated with infliximab two cases of severe
CPDD resistant to NSAIDs treatment.
2. Methods and Results
2.1. Case Report 1. A 30-year-old male patient presented with
bilateral ankle swelling and pain. On examination, there was
reduced range of motion (ROM) in both ankles causing gait
difficulties and requiring adapted footwear. X-rays revealed
narrowing of the articular space, sclerosis as well as bridging
in both ankles, calcification of the iliolumbar ligament, and
pelvic and femoral entheseal ossification.
Subsequently, his arthritis followed a relapsing-remitting
course, with several episodes of acute synovitis in knees,
wrists, metacarpophalangeal joints (MCPs), shoulders, and
spine. A diagnosis of CPDD/DISH was made at age 49 based
on X-rays that showed huge anterior longitudinal ligament
calcification of the entire spine and massive iliolumbar calci-
fication with restriction of lumbar spine mobility (Figure 1).
He also had bilateral gonarthrosis, patellofemoral arthrosis,
fusion of both ankles, and huge femoral neck osteophyto-
sis. He had a history of severe alcohol abuse. Laboratory
tests identified high ferritin (>800 ng/mL) and erythrocyte
sedimentation rate (ESR) of 60mm/hr. Plasma and urine
levels, fluoride, calcium, phosphate, and magnesium were
normal. Moreover, serum levels of growth hormone (GH),
parathormone (PTH), thyroid hormones (THs), and vitamin
D were also normal. Rheumatoid factor and antinuclear
antibodies (ANA) were normal or negative. Due to the high
ferritin level, HFE mutations were investigated; he was a
compound heterozygote for C282Y and H63D, but there
were no excess liver iron stores in MRI. HLA-B27 was
negative. ANKH sequencing found no pathogenic variants.
There was no psoriasis, inflammatory bowel disease, or other
comorbidities. Kidney failure and axial DISH were reported
in two brothers. He was not taking vitamin D analogues.
At age 51, he was almost completely in bed with severe
arthritis related pain and chronic arthritic disease in the
lower limbs, with severe reduction in ankle ROM and
flexion deformities of both knees, making walking almost
impossible. Symptoms were poorly controlled with anal-
gesics, NSAIDs, and intra-articular and oral steroids. He was
therefore started on intravenous infliximab 3mg/kg each 8
weeks.This resulted in a dramatic improvement with absence
of pain and a complete resolution of all tender and swollen
joints within 3 months of treatment. Gradual improvement
of knee movements led to improved gait and the patient can
now walk using a cane and adapted footwear. Over time,
discontinuation of all comedications was possible and the
patient continues to be treated with infliximab administered
every 8 weeks. Significant improvement was observed on
the activity indexes until now after nine years of follow-up
(Figure 2). ESR and ferritin are now normal. No relevant side
effects of infliximab were registered.
2.2. Case Report 2. A male patient developed swelling and
pain in the MCP joints and proximal interphalangeal joints
(PIPs) III, IV, and V of both hands when he was 30 years
old, followed by pain in both knees, elbows, and shoulders.
Figure 1: Lumbar spine and iliolumbar ligament calcification.
Inflammatory lumbar back pain developed around age of 40
years. At age of 50 years, CPPD crystals were identified in a
knee effusion and the diagnosis of CPPD chondrocalcinosis
was made.
By 55 years of age, he had continuous severe polyarthritis
affecting fingers, elbows, and knees and flexion contracture
of PIPs in both hands with painful forced reduction, impor-
tant extension limitation of right elbow, and deformity of
both tibial spines. X-rays at this stage showed important
osteophytosis of anterolateral spine and femoral heads, bilat-
eral patellofemoral arthrosis, subluxations, narrowing, and
metacarpal heads osteophytes ofMCP II-III-IV in both hands
(Figure 3). There was also bilateral periarticular soft tissue
calcification of patella, elbow, and inferior calcaneum surface
(Figure 3). He had dorsolumbar back pain frequently but
no significant restriction of lumbar mobility was found. A
similar clinical and radiological phenotype was present in
several family members, and pyrophosphate crystals were
identified in the knee synovial fluid from the youngest (25
years old) following several episodes of pseudogout.
Laboratory tests showed normal ESR, C-reactive protein
(CRP), ferritin, calcium, magnesium, phosphate, PTH, GH,
vitamin D, and thyroid hormones (THs). Rheumatoid factor
and ANA were negative. He was a H63D heterozygote and
HLA-B27 was not identified. ANKH sequencing found no
pathogenic variants. There was no psoriasis, inflammatory
bowel disease, or uveitis. The patient also had a diagnosis of
coronary artery disease and atrial fibrillation.
He was refractory to multiple NSAIDs. Intravenous
infliximab (3mg/kg) was started at age 56, each 8 weeks. A
major reduction of pain and swelling was observed within
weeks, with complete absence of pain in peripheral and axial
joints by 4 months. There was a dramatic improvement of
hand function with painless reduction of flexion contracture
of PIP. There was also improvement in the activity indexes
(Figure 2). No side effects of infliximab were observed.
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Figure 2: Evolution of the activity indexes in both cases; T0 refers to the first administration of infliximab.
Figure 3: Metacarpal heads osteophytes, MCPs subluxations, and joint narrowing; calcifications of patella and elbow.
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3. Discussion
Current understanding of how CPPD crystals interact with
the caspase-1-activating NACHT, LRR, and PYD domains
containing protein 3 (NALP3) inflammasome of the innate
immune system has given novel insights into themechanisms
by which these crystals cause episodic joint inflammation.
Nucleotide-binding oligomerization domain- (NOD-) like
receptors (NLRs) such as NALP3 have been found to sense
endogenous stress signals known as damaged associated
molecular patterns or DAMPs [14, 15]. Among several NLRs
that form inflammasome platforms, the most studied are
NALP1, NALP3 (NLRP3), and IPAF. Pyrophosphate and
monosodium urate monohydrate (MSUM) crystals respon-
sible for acute and chronic crystal arthropathies were iden-
tified as danger signals activating the caspase-1-activating
NALP3 inflammasome, inducing pro-IL-1𝛽 maturation in
macrophages [16].
A role for TNF in crystal induced arthritis has been sug-
gested by the demonstration that exposure of mononuclear
and synovial cells to either monosodium urate monohydrate
(MSUM) or CPPD crystals leads to TNF-𝛼 production that
is able to stimulate the migration of neutrophils from circu-
lating blood into the joints [17, 18]. Human neutrophils at
inflammatory sites are an important source of inflammatory
cytokines, and synovial fluid from diseased joints from
patients with gout or pseudogout contains large numbers
of neutrophils which migrate from circulating blood into
the joint. The interaction of CPPD or MSUM crystals with
neutrophils at the synovial joint is thought to give rise to
the inflammation found in these diseases and to increase the
production of TNF-alpha, IL-8, andGM-CSF, whichmay also
increase the migration of neutrophils from the circulating
blood [19, 20].
Infliximab is a chimeric monoclonal anti-TNF antibody
used to treat several inflammatory diseases, namely, the
spondyloarthropathies (ankylosing spondylitis and psoriatic
arthritis), rheumatoid arthritis, and inflammatory bowel
disease [12, 13, 21]. It is not part of standard care protocols for
patientswithCPPDchondrocalcinosis. To our knowledge,we
are reporting the first two cases of patients with severe CPDD
treated with infliximab. Both patients had a peculiar pheno-
type, already described by several authors, with enthesopathic
calcifications, in both peripheral and axial skeletons, which
were initially treated with NSAIDs and analgesics without
significant improvement. Treatment with infliximab leads to
a rapid reduction in pain and improvement of function in
both patients, and this improvement was maintained until
now (9 years). There were no major side effects and patients
now only take analgesics and NSAIDs occasionally in addi-
tion to their infliximab treatment. Furthermore, in the first
patient, after infliximab treatment, ESR and ferritin returned
to normal levels. In both patients, after nine years of follow-
up, anti-TNF treatment was shown to be effective and safe.
4. Conclusion
We suggest that the efficacy of TNF-inhibitor therapy in
severe CPDD arthropathy should be further investigated.
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